46 related articles for article (PubMed ID: 34843906)
1. The potential role of c-MYC and polyamine metabolism in multiple drug resistance in bladder cancer investigated by metabonomics.
Zhu Y; Piao C; Zhang Z; Jiang Y; Kong C
Genomics; 2022 Jan; 114(1):125-137. PubMed ID: 34843906
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer.
Lin W; Sun J; Sadahira T; Xu N; Wada K; Liu C; Araki M; Xu A; Watanabe M; Nasu Y; Huang P
Int J Biol Sci; 2021; 17(12):3255-3267. PubMed ID: 34421363
[TBL] [Abstract][Full Text] [Related]
3. Elevated expression of HIGD1A drives hepatocellular carcinoma progression by regulating polyamine metabolism through c-Myc-ODC1 nexus.
Zhang H; Li X; Liu Z; Lin Z; Huang K; Wang Y; Chen Y; Liao L; Wu L; Xie Z; Hou J; Zhang X; Liu H
Cancer Metab; 2024 Feb; 12(1):7. PubMed ID: 38395945
[TBL] [Abstract][Full Text] [Related]
4. Polyamine-mediated ferroptosis amplification acts as a targetable vulnerability in cancer.
Bi G; Liang J; Bian Y; Shan G; Huang Y; Lu T; Zhang H; Jin X; Chen Z; Zhao M; Fan H; Wang Q; Gan B; Zhan C
Nat Commun; 2024 Mar; 15(1):2461. PubMed ID: 38504107
[TBL] [Abstract][Full Text] [Related]
5. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
Shi ZD; Hao L; Han XX; Wu ZX; Pang K; Dong Y; Qin JX; Wang GY; Zhang XM; Xia T; Liang Q; Zhao Y; Li R; Zhang SQ; Zhang JH; Chen JG; Wang GC; Chen ZS; Han CH
Mol Cancer; 2022 Feb; 21(1):37. PubMed ID: 35130920
[TBL] [Abstract][Full Text] [Related]
6. Genome-Wide Screening Identifies Gene AKR1C1 Critical for Resistance to Pirarubicin in Bladder Cancer.
Nie Z; Gao Y; Chen M; Peng Y; Guo N; Cao H; Huang D; Gao X; Zhang S
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173953
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the Reprograming of Colorectal Cancer Metabolism Using Genome-Scale Metabolic Modeling.
Zhang C; Aldrees M; Arif M; Li X; Mardinoglu A; Aziz MA
Front Oncol; 2019; 9():681. PubMed ID: 31417867
[TBL] [Abstract][Full Text] [Related]
8. Dual Inhibition of Pirarubicin-Induced
Peng M; Deng J; Zhou S; Xiao D; Long J; Zhang N; He C; Mo M; Yang X
Front Pharmacol; 2019; 10():1159. PubMed ID: 31649535
[TBL] [Abstract][Full Text] [Related]
9. JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy.
Rosario SR; Jacobi JJ; Long MD; Affronti HC; Rowsam AM; Smiraglia DJ
Mol Cancer Res; 2023 Jan; 21(1):24-35. PubMed ID: 36166196
[TBL] [Abstract][Full Text] [Related]
10. c-MYC-Driven Polyamine Metabolism in Ovarian Cancer: From Pathogenesis to Early Detection and Therapy.
Chen Y; León-Letelier RA; Abdel Sater AH; Vykoukal J; Dennison JB; Hanash S; Fahrmann JF
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765581
[TBL] [Abstract][Full Text] [Related]
11. Stepwise molecular mechanisms responsible for chemoresistance in bladder cancer cells.
Mun JY; Baek SW; Jeong MS; Jang IH; Lee SR; You JY; Kim JA; Yang GE; Choi YH; Kim TN; Chu IS; Leem SH
Cell Death Discov; 2022 Nov; 8(1):450. PubMed ID: 36344487
[TBL] [Abstract][Full Text] [Related]
12. Polyamines: the pivotal amines in influencing the tumor microenvironment.
Holbert CE; Casero RA; Stewart TM
Discov Oncol; 2024 May; 15(1):173. PubMed ID: 38761252
[TBL] [Abstract][Full Text] [Related]
13. Is switching intravesical chemotherapeutic agents beneficial in short-term recurrent high-risk non-muscle-invasive bladder tumors? A 5-year retrospective study.
Chen S; Sun G; Chen X; Salgado T; Wu S; Hu H; Liu R; Qie Y
BMC Urol; 2024 Jan; 24(1):25. PubMed ID: 38297256
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic Signatures of Treatment Response in Bladder Cancer.
Vieira de Sousa T; Guedes de Pinho P; Pinto J
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139377
[TBL] [Abstract][Full Text] [Related]
15. Deciphering the Mysterious Relationship between the Cross-Pathogenetic Mechanisms of Neurodegenerative and Oncological Diseases.
Aleksandrova Y; Neganova M
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834214
[TBL] [Abstract][Full Text] [Related]
16. Predicting lung adenocarcinoma prognosis, immune escape, and pharmacomic profile from arginine and proline-related genes.
Wang Z; Zhang J; Shi S; Ma H; Wang D; Zuo C; Zhang Q; Lian C
Sci Rep; 2023 Sep; 13(1):15198. PubMed ID: 37709932
[TBL] [Abstract][Full Text] [Related]
17. Construction of a prognostic model based on eight ubiquitination-related genes
Hao Y; Guy MM; Liu Q; Li R; Mao Z; Jiang N; Wang B; Cui B; Zhang W
Front Genet; 2023; 14():1142938. PubMed ID: 36999051
[No Abstract] [Full Text] [Related]
18. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
[TBL] [Abstract][Full Text] [Related]
19. Identification of the effect and mechanism of Yiyi Fuzi Baijiang powder against colorectal cancer using network pharmacology and experimental validation.
Xiang B; Geng R; Zhang Z; Ji X; Zou J; Chen L; Liu J
Front Pharmacol; 2022; 13():929836. PubMed ID: 36353478
[No Abstract] [Full Text] [Related]
20. Integrin Signaling Shaping BTK-Inhibitor Resistance.
Polcik L; Dannewitz Prosseda S; Pozzo F; Zucchetto A; Gattei V; Hartmann TN
Cells; 2022 Jul; 11(14):. PubMed ID: 35883678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
